

## New Dental Materials

Septodont recently announced the purchase of **OraVerse®** (phentolamine mesylate) from Novalar Pharmaceuticals. According to the manufacturer, OraVerse® reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used. OraVerse® is indicated for reversal of the soft-tissue anesthesia (i.e., anesthesia of the lip and tongue) and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse® is not recommended for use in children less than six years old or weighing less than 15 kg (33 lbs). In clinical trials, the most common adverse events with OraVerse® vs. the control were post-procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse®, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. OraVerse® is available as a 10 carpule pack for \$110.00 (suggested retail/government) or in packages of 50 for \$550.00 (suggested retail/government).



**For additional information contact Septodont USA at:**

(800) 872-8305,

(717) 286-0100,

(717) 560-3480 FAX, or

[www.septodontusa.com/home](http://www.septodontusa.com/home).